T1	Participants 60 150	in postoperative rectal cancer patients treated with adjuvant concurrent chemoradiotherapy
T2	Participants 317 425	n postoperative rectal cancer patients who received capecitabine-based postoperative chemoradiotherapy (CRT)
T3	Participants 435 492	Four hundred patients with stage II and III rectal cancer
T4	Participants 1526 1553	patients without severe AEs
T5	Participants 2092 2117	patients with AA genotype
T6	Participants 2218 2246	hose with GG or GA genotypes
T7	Participants 2443 2499	in postoperative stage II and III rectal cancer patients
